Faculty Collaboration Database

Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer. Cancer Epidemiol Biomarkers Prev 2011 May;20(5):1028-31

Date

03/19/2011

Pubmed ID

21415361

Pubmed Central ID

PMC3176661

DOI

10.1158/1055-9965.EPI-11-0053

Scopus ID

2-s2.0-79955782734 (requires institutional sign-in at Scopus site)

Abstract

BACKGROUND: We previously reported an association between rs2660753, a prostate cancer susceptibility polymorphism, and invasive epithelial ovarian cancer (EOC; OR = 1.2, 95% CI=1.0-1.4, P(trend) = 0.01) that showed a stronger association with the serous histological subtype (OR = 1.3, 95% CI = 1.1-1.5, P(trend) = 0.003).

METHODS: We sought to replicate this association in 12 other studies comprising 4,482 cases and 6,894 controls of white non-Hispanic ancestry in the Ovarian Cancer Association Consortium.

RESULTS: No evidence for an association with all cancers or serous cancers was observed in a combined analysis of data from the replication studies (all: OR = 1.0, 95% CI = 0.9-1.1, P(trend) = 0.61; serous: OR = 1.0, 95% CI = 0.9-1.1, P(trend) = 0.85) or from the combined analysis of discovery and replication studies (all: OR = 1.0, 95% CI = 1.0-1.1, P(trend) = 0.28; serous: OR = 1.1, 95% CI = 1.0-1.2, P(trend) = 0.11). There was no evidence for statistical heterogeneity in ORs across the studies.

CONCLUSIONS: Although rs2660753 is a strong prostate cancer susceptibility polymorphism, the association with another hormonally related cancer, invasive EOC, is not supported by this replication study.

IMPACT: Our findings, based on a larger sample size, emphasize the importance of replicating potentially promising genetic risk associations.

Author List

Amankwah EK, Kelemen LE, Wang Q, Song H, Chenevix-Trench G, Australian Ovarian Cancer Study Group, Beesley J, Webb PM, Australian Cancer Study (Ovarian Cancer), Pearce CL, Wu AH, Pike MC, Stram DO, Chang-Claude J, Wang-Gohrke S, Ness RB, Goode EL, Cunningham JM, Fridley BL, Vierkant RA, Tworoger SS, Whittemore AS, McGuire V, Sieh W, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Rossing MA, Doherty JA, Goodman MT, Carney ME, Lurie G, Wilkens LR, Kjær SK, Høgdall E, Cramer DW, Terry KL, Garcia-Closas M, Yang H, Lissowska J, Anton-Culver H, Ziogas A, Schildkraut JM, Berchuck A, Pharoah PD, Ovarian Cancer Association Consortium

Author

Ernest Amankwah PhD Director, Associate Professor in the Clinical and Translational Science Institute department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Biomarkers, Tumor
Case-Control Studies
Female
Genetic Predisposition to Disease
Genotype
Humans
Male
Microsatellite Repeats
Neoplasm Invasiveness
Ovarian Neoplasms
Polymorphism, Single Nucleotide
Prognosis
Prostatic Neoplasms
Risk Factors